CAR-Macrophage/Transgene/Cytokine/Biomarker RNA Biodistribution Analysis

RNA In Situ Hybridization (RNA ISH) assay is a valuable technique in CAR-Macrophage/transgene/Cytokine/Biomarker RNA Biodistribution analysis, especially in the context of cell therapy development. As a leading technology provider, Creative Bioarray's elite scientists have broad experience in CAR-Macrophage/transgene/Cytokine/Biomarker RNA Biodistribution Analysis (RNA ISH method), which can supply the best service for you.

Fig. 1. RNA ISH assay for detection. RNA ISH probes were designed to target the 3' UTR of the CAR vector and the transgene sequences.

The use of RNA ISH technique in CAR-Macrophage/transgene/Cytokine/Biomarker RNA Biodistribution Analysis offers several advantages:

• High Sensitivity: RNA ISH assay is highly sensitive and can detect even low levels of RNA expression. This helps to accurately measure the biodistribution of CAR-macrophages, transgenes, cytokines, and biomarkers during cell therapy.
• Spatial Distribution: Unlike other techniques, RNA ISH assay allows for the study of spatial distribution of the RNA within a tissue. This is critical in understanding how the biological factors are distributed and interact within the biological specimen.
• Versatility: It can be used to analyze various types of RNA including mRNA, non-coding RNA and viral RNA, making it extremely versatile in biodistribution analysis in cell therapy.
• Multiplexing: RNA ISH assay allows simultaneous detection of multiple targets in a single specimen. It is beneficial in studying complex cellular responses involving cytokines, transgenes, and biomarkers.

Overall, RNA ISH assay offers multiple advantages like high sensitivity, localization, ability to multiplex, and high specificity, making it a powerful tool in studying CAR-macrophages, transgene, cytokine and biomarker RNA biodistribution in cell therapy.

Tabel 1. Advantages and disadvantages of different methods for detecting biodistribution

Features of CAR-Macrophage/Transgene/Cytokine/Biomarker RNA Biodistribution Analysis (RNA ISH method)

• Detection of activated CAR-Macrophage cells in the tissue context
• Codon-optimized transgene and biomarker expression analysis
• Custom probes designed within 1-2 weeks
• Fastest turnaround time

Benefits of CAR-Macrophage/transgene/Cytokine/Biomarker RNA Biodistribution Analysis (RNA ISH method)

• Detect low levels of gene expression across all normal tissues in animal models and human samples
• Assess cell-specific target expression in normal tissues and expression heterogeneity in tumor tissues
• Visualize and quantify CAR-Macrophage cell infiltration and activation in tumor and off-tumor tissues
• Simultaneously detect CAR vector and cytokines, Macrophage cell markers, or other cell-type markers

Creative Bioarray offers CAR-Macrophage/Transgene/Cytokine/Biomarker RNA Biodistribution Analysis for you as follows:

• Probe design
• Probe synthesis
• ISH staining
• Imaging
• Data analysis

Quotation and ordering

Our customer service representatives are available 24hr a day! We thank you for considering Creative Bioarray as your CAR-Macrophage/Transgene/Cytokine/Biomarker RNA Biodistribution Analysis partner.

References

1. Sadelain M., Brentjens R., Rivière I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013;3:388–398. doi: 10.1158/2159-8290.CD-12-0548.
2. Grupp S.A., Kalos M., Barrett D., Aplenc R., Porter D.L., Rheingold S.R., Teachey D.T., Chew A., Hauck B., Wright J.F., et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 2013;368:1509–1518. doi: 10.1056/NEJMoa1215134
3. Daniyan A.F., Brentjens R.J. At the Bench: Chimeric antigen receptor (CAR) T cell therapy for the treatment of B cell malignancies. J. Leukoc. Biol. 2016;100:1255–1264. doi: 10.1189/jlb.5BT1215-556RR.
4. Jin R., Hao J., Yi Y., Sauter E., Li B. Regulation of macrophage functions by FABP-mediated inflammatory and metabolic pathways. Biochim. Biophys. Acta Mol. Cell Biol. Lipids. 2021;1866:158964. doi: 10.1016/j.bbalip.2021.158964.
5. Chen Y., Yu Z., Tan X., Jiang H., Xu Z., Fang Y., Han D., Hong W., Wei W., Tu J. CAR-macrophage: A new immunotherapy candidate against solid tumors. Biomed. Pharmacother. 2021;139:111605. doi: 10.1016/j.biopha.2021.111605.
6. Varol C., Mildner A., Jung S. Macrophages: Development and tissue specialization. Annu. Rev. Immunol. 2015;33:643–675. doi: 10.1146/annurev-immunol-032414-112220.
7. Orecchioni M., Ghosheh Y., Pramod A.B., Ley K. Macrophage Polarization: Different Gene Signatures in M1(LPS+) vs. Classically and M2(LPS−) vs. alternatively activated macrophages. Front. Immunol. 2019;10:1084. doi: 10.3389/fimmu.2019.01084.